Blog

Is Our Short List a Reflection of Comfort or of the Market?

Is Our Short List a Reflection of Comfort or of the Market?

In nearly every executive search conversation I have with founders, CEOs, and board members in Life Sciences, there is an understandable instinct that surfaces early. “We already know who we would ...
Biotech executive compensation mix: CEO pay is more equity-heavy, while the CFO mix moves closer at later company stages.

Biotech Executive Compensation Mix by Company Stage

How much an executive is paid is only part of the compensation decision. The balance among salary, cash incentives, and equity also matters, particularly when a biotechnology company is preparing ...
When the science is right, but the story is wrong

When the science is right, but the story is wrong

A life sciences company can have compelling science, a strong intellectual property position, promising data, and a highly respected scientific team, yet still struggle to convince the people whose support ...
What happens when everyone in the executive team is a specialist?

What happens when everyone in the executive team is a specialist?

A life sciences company can have an impressive executive team on paper and still struggle to make good decisions. The Chief Scientific Officer understands the science. The Chief Medical Officer ...
The most expensive executive hire may be the one everyone agreed on

The most expensive executive hire may be the one everyone agreed on

There is a particular moment in an executive search when everything appears to line up. The candidate has the right experience. The résumé makes sense. The references are strong. The ...
GeneCoda comparison of indexed and non-indexed biotech executive compensation before and after adjusting for role, stage, and company scale.

Do Public Biotech Companies in Major Indices Pay Executives More?

Do Public Biotech Companies in Major Indices Pay Executives More? We expected the answer to be yes. Public biotech companies included in major indices such as XBI, IBB, and NBI ...
The executive who was perfect for the last five years may be wrong for the next five

The executive who was perfect for the last five years may be wrong for the next five

A successful executive hire creates a natural temptation to stop questioning the appointment. The company grows. The executive delivers. The board gains confidence. The leadership team develops a rhythm. Years ...
Why your next great life sciences leader may not look like your last one

Why your next great life sciences leader may not look like your last one

For decades, life sciences companies have had a relatively familiar idea of what a senior executive should look like. A scientist with decades of industry experience. A commercial leader who ...
eneCoda® Public Biotech Intelligence graphic showing that 12.2% of 393 public biotech companies have at least one substantive dual-role executive, and 58% of identified dual-role executives involve the CFO function.

The Dual-Role Biotech Executive: Why Finance Sits at the Center of Role Consolidation

Executive leadership structures in public biotech are not always as neatly separated as an organizational chart might suggest. GeneCoda® analyzed the latest usable executive compensation disclosures across 393 active public ...